Lehne's Pharmacology for Nursing Care 10th Edition TEST
BANK(Chapter 1-110).
Chapter 3: Drug Regulation, Development, Names, and Infor
7 b 7 b 7 b 7 b 7 b 7 b 7 b
mat ion Test Bank
7b 7 b 7 b
MULTIPLE 7 b CHOICE
1. A nurse educator is conducting a
7 b continuing education class on pharmacology.
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
To evaluate the learning of the nurses in the class, the nurse educat
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
or asks, ―Whi ch drug name is a generic drug name?‖ Which is the
7 b 7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7 correct response? a. Acet aminophen
b 7 b 7 b 7 b 7b
b. Tylenol
c. Cipro
d. Motrin
ANS: A 7 b
Acetaminophen is the generic name. Tylenol, Cipro, and Motrin are all trade nam 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
es.
DIF: Cognitive Level: Comprehension REF: Table 3-
7 b 7 b 7 b 7b7b 7 b 7 b
3: The Three Types ofs2Drug Names TOP: Nursing Process: Diagnosis
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
Therap ies 7 b
2. The FDA Amendments Act (FDAAA) was passed in 2007 to address
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7
b which as pect of dr ug safety? 7 b 7b 7 b 7 b 7 b 7 b
a. Allowing pharmaceutical companies to identif 7 b 7 b 7 b 7 b
y off- 7b
label uses ofs2medications approved for othe 7 b 7 b 7 b 7 b 7 b
rs uses 7 b
b. Evaluating drug safety information that emerges after a drug has 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
been appr oved and is in use 7 b 7b 7 b 7 b 7 b 7 b
c. Expediting the approval process of the U.S. Food and Drug Adm 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
inistration (FDA) s o that needed drugs can get to market more 7b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7
quickly b
d. Requiring manufacturers to notify patients before removing a drug from
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
the mark et 7 b 7b
ANS: 7 b B
The FDAAA was passed to enable the Food and Drug Administration t
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
o continue oversight
7 b 7b
ofs2a drug after granting it approval so that changes in labeling 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7 could be
b 7 b
made as necessary 7 b 7 b
, and postmarketing risks could be tracked and identified. 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7 A pr ovision ofs2the FDA Moderniza tion Act (FDAMA), passed in 199
b 7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7, allows drug c ompanies to promote their products for of f-
7 b 7 b 7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b
label uses as long as they promise to conduct studies to support their
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
claims. Regu lations to permit accelerated approval ofs2drugs for life-
7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b
,Test Bank Lehne's Pharmacology for Nursing Care, 11th E
7b 7b 7b 7b 7b 7b 7b 7b 7b
di tion by Jacqueline Burchum, Laura Rosenthal Chapte
7 b 7 b 7 b 7 b 7 b 7 b 7 b
r
threatening diseasess2weres2adopteds2ins21992s2bys2thes2FDA.s2The requirement that drug
compani
1- 7 b 7 b 7 b 7 b
es notify112|Complete
patientss26 months Guide
7 b A+
before removing a drug from the
7 b 7 b 7 b 7 7b b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
market is a provision ofs2the F DAMA.
7 b 7b 7 b 7 b 7 b 7 b
DIF: Cognitive
7 b 7 b Level: 7 b Compreh
ens ion
7b REF: 7 b Landmark Drug Legislation
7 b 7 b
TOP: Nursing Process: Evaluation
7 b 7 b 7 b7 b 7 b 7 b
MSC: NCLEX Client Needs Category:
7 b 7 b 7 b 7 b 7 b Physiologic 7 b Integrity: 7 b Pharmacologic 7 b and 7 b Pare
nteral Th erapies
7 b 7b
, 3. A nursing student asks a nurse about pharmaceutical research and wants
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7
b to know the purpo se of
7 b 7b randomization in
7 b 7 b 7 b 7 b
drug trials. The nurse explains that
7 b 7 b 7 b
randomi zation is used to: 7b 7 b
a. ensure that differences in outcomes are the result ofs2treatment an
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
d not di fferences in subjects.
7 b 7 b 7b 7 b 7 b
b. compare the outcome caused by the treatment to the outcome caused
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b b
y no treat ment.
7 b 7 b 7b
BANK(Chapter 1-110).
Chapter 3: Drug Regulation, Development, Names, and Infor
7 b 7 b 7 b 7 b 7 b 7 b 7 b
mat ion Test Bank
7b 7 b 7 b
MULTIPLE 7 b CHOICE
1. A nurse educator is conducting a
7 b continuing education class on pharmacology.
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
To evaluate the learning of the nurses in the class, the nurse educat
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
or asks, ―Whi ch drug name is a generic drug name?‖ Which is the
7 b 7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7 correct response? a. Acet aminophen
b 7 b 7 b 7 b 7b
b. Tylenol
c. Cipro
d. Motrin
ANS: A 7 b
Acetaminophen is the generic name. Tylenol, Cipro, and Motrin are all trade nam 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
es.
DIF: Cognitive Level: Comprehension REF: Table 3-
7 b 7 b 7 b 7b7b 7 b 7 b
3: The Three Types ofs2Drug Names TOP: Nursing Process: Diagnosis
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
Therap ies 7 b
2. The FDA Amendments Act (FDAAA) was passed in 2007 to address
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7
b which as pect of dr ug safety? 7 b 7b 7 b 7 b 7 b 7 b
a. Allowing pharmaceutical companies to identif 7 b 7 b 7 b 7 b
y off- 7b
label uses ofs2medications approved for othe 7 b 7 b 7 b 7 b 7 b
rs uses 7 b
b. Evaluating drug safety information that emerges after a drug has 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
been appr oved and is in use 7 b 7b 7 b 7 b 7 b 7 b
c. Expediting the approval process of the U.S. Food and Drug Adm 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
inistration (FDA) s o that needed drugs can get to market more 7b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7
quickly b
d. Requiring manufacturers to notify patients before removing a drug from
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
the mark et 7 b 7b
ANS: 7 b B
The FDAAA was passed to enable the Food and Drug Administration t
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
o continue oversight
7 b 7b
ofs2a drug after granting it approval so that changes in labeling 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7 could be
b 7 b
made as necessary 7 b 7 b
, and postmarketing risks could be tracked and identified. 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7 A pr ovision ofs2the FDA Moderniza tion Act (FDAMA), passed in 199
b 7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
7, allows drug c ompanies to promote their products for of f-
7 b 7 b 7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b
label uses as long as they promise to conduct studies to support their
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
claims. Regu lations to permit accelerated approval ofs2drugs for life-
7 b 7b 7 b 7 b 7 b 7 b 7 b 7 b
,Test Bank Lehne's Pharmacology for Nursing Care, 11th E
7b 7b 7b 7b 7b 7b 7b 7b 7b
di tion by Jacqueline Burchum, Laura Rosenthal Chapte
7 b 7 b 7 b 7 b 7 b 7 b 7 b
r
threatening diseasess2weres2adopteds2ins21992s2bys2thes2FDA.s2The requirement that drug
compani
1- 7 b 7 b 7 b 7 b
es notify112|Complete
patientss26 months Guide
7 b A+
before removing a drug from the
7 b 7 b 7 b 7 7b b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
market is a provision ofs2the F DAMA.
7 b 7b 7 b 7 b 7 b 7 b
DIF: Cognitive
7 b 7 b Level: 7 b Compreh
ens ion
7b REF: 7 b Landmark Drug Legislation
7 b 7 b
TOP: Nursing Process: Evaluation
7 b 7 b 7 b7 b 7 b 7 b
MSC: NCLEX Client Needs Category:
7 b 7 b 7 b 7 b 7 b Physiologic 7 b Integrity: 7 b Pharmacologic 7 b and 7 b Pare
nteral Th erapies
7 b 7b
, 3. A nursing student asks a nurse about pharmaceutical research and wants
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7
b to know the purpo se of
7 b 7b randomization in
7 b 7 b 7 b 7 b
drug trials. The nurse explains that
7 b 7 b 7 b
randomi zation is used to: 7b 7 b
a. ensure that differences in outcomes are the result ofs2treatment an
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b
d not di fferences in subjects.
7 b 7 b 7b 7 b 7 b
b. compare the outcome caused by the treatment to the outcome caused
7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b 7 b b
y no treat ment.
7 b 7 b 7b
